Citalopram

Elopram, Seropram e altri

Bibliografia - Quali fonti bibliografiche per Citalopram?

1. Abman S.H., Pediatr. Pulmonol. Suppl., 1999, 18, 201.


2. Adson DE, Kotlyar M., Ann. Pharmacother., 2003, 37, 1804.


3. Alaghband-Rad J., Hakimshooshtary M., Eur. Child. Adolesc. Psychiatry, 2009, 18 (3), 131.


4. Altshuler L.L. et al., J. Clin. Psychiatry, 1995, 56, 243.


5. Alwan S. et al., NEJM, 2007, 356, 2684.


6. Anderberg U.M. et al., Eur. J. Pain, 2000, 4, 27.


7. Bergeron L. et al., Ann. Pharmacother., 2005, 39, 956.


8. Bondolfi G. et al., Psychopharmacology (Berl), 1996, 128 (4), 421.


9. Borba C.P., Henderson D.C., J. Clin. Psychiatry. 2000, 61, 301.


10. Bouchard J.M. et al., Acta Psychiatric. Scand., 1987, 76, 583.


11. Casper R.C. et al., J. Pediatr., 2003, 142, 402.


12. Chambers C.D. et al., NEJM, 2006, 354, 579.


13. Chris C., Australian Prescriber 2006, 29, 71.


14. Dalton S.O. et al., Arch. Intern. Med., 2003, 163, 59.


15. Danish University Antidepressant Group, Psychopharmacology, 1986, 90, 131.


16. Drye L.T. et al., PloS One, 2014, 9 (6), e98426.


17. Ekselius L. et al., Int. Clin. Psychopharmacol., 1997, 12, 323.


18. Ertel G.J., Nesbit T.W., J. Pharm. Technol., 2002, 19, 91.


19. Expertise Collective Inserm, Les édition Inserm: Paris; 2003.


20. Gravem A. et al., Acta Psychiatr. Scand., 1987, 75, 478.


21. Gulseren L. et al., Arch. Med. Res., 2005, 36 (2), 159.


22. Haffmans P.M.J. et al., Int. Clin. Psychopharmacol., 1996, 11, 157.


23. Heikkinen T. et al., Clin. Pharmacol. Ther., 2002, 72 (2), 184.


24. Health Canada's Can. Adverse Drug React., Newsl., 2000, 10 (3), 4.


25. Isenberg K.E., J. Clin. Psychiatry, 1990, 51, 169.


26. Itil T.M. et al., Progress in neuro-psychopharmacology and biological Psychiatry, 1984, 8, 397.


27. Jureidini J.N. et al., BMJ, 2004, 328, 879.


28. Kirby D. et al., Internet J. Ger. Psychiatry, 2002, 17, 231.


29. Krag-Sorensen P. et al., Acta Pharmacol. Toxicol., 1981, 48, 53.


30. Kronenberg S. et al., J. Child. Adolesc. Psychopharmacol., 2007, 17 (6), 741.


31. Kwon P., Lefkowitz W., Paediatric Annals, 2008, 37, 128.


32. Laine K. et al., Arch. Gen. Psychiatry, 2003, 60, 720.


33. Lancet, 2009, 373, 746.


34. Layton D. et al., Eur. J. Clin. Pharmacol., 2001, 57, 167.


35. Leonpacher A.K. et al., Am. J. Psychiatry, 2016, 173 (5), 473.


36. Lesperance F. et al., JAMA, 2007, 297, 367 (studio CREATE).


37. Louik C. et al., NEJM, 2007, 356, 2675.


38. Lullmann-Rauch R., Nassberger L., Acta Pharmacol. Toxicol., 1983, 52 (3), 161.


39. Malm H. et al., Obstet. Gynecol., 2005, 106, 1289.


40. Mason P.J. et al., Medicine, 2000, 79, 201.


41. Mendels J. et al., 30th Annual Meeting of the New Clinical Drug Evaluation Unit, 1990, 29 Maggio – 1 giugno, Florida.


42. Miller L.J., Ann. Pharmacother., 2000, 34 (2), 269.


43. Mills J.L., NEJM, 2006, 354, 636.


44. Milne R.J., Goa K.L., Drugs, 1991, 41 (3), 450.


45. Montgomery S.A. et al., Int. Clin. Psychopharmacol., 1992, 6 (Suppl. 5), 65.


46. Montgomery S.A. et al., Int. Clin. Psychopharmacol., 1993, 8, 181.


47. Montgomery S.A. et al., Int. Clin. Psychopharmacol., 1994, 9 (Suppl. 1), 35.


48. Morag I. et al., J. Toxicol. Clin. 2004, 42, 97.


49. Movig K.L. et al., Arch. Intern. Med., 2003, 163, 2354.


50. Muldoon C. et al., Int. Clin. Psychopharmacol., 1996, 11 Suppl. 1, 35.


51. Naranjo C.A. et al., Clin. Pharmacol. Ther., 1992, 51, 729.


52. Nicholson A. et al., Eur. Heart J., 2006, 27, 2763.


53. Norregaard J. et al., Pain, 1995, 61, 445.


54. Nemeroff C.B. Psychopharmaco. Bull., 2003, 37(1), 96.


55. Nulman I. et al., Am. J. Psychiatry, 2002, 159, 1889.


56. Nyth A.L. et al., Acta Psychiatric. Scand., 1992, 86, 138.


57. Oberlander T.F. et al., Pediatr. Res., 2002, 51, 443.


58. Orlova Y. et al., JAMA Neurol., 2018, doi: 10.1001/jamaneurol.2017.5144.


59. Patris M. et al., Int. Clin. Psychopharmacol., 1996, 11, 129.


60. Patron C. Ferrier I.N., BMJ, 2005, 334, 529.


61. Pederson O.L. et al., Psychopharmacology, 1982, 77, 199.


62. Porsteinsson A.P. et al., JAMA, 2014, 311 (7), 682.


63. Prior F.H., et al., Med. J. Austr., 2002, 176, 240.


64. Rosenberg C. et al., Int. Clin. Psychopharmacol., 1994, 9 Suppl. 1, 41.


65. Sala M. et al., Annals of General Psychiatry, 2005, 4, 1.


66. Sansone R.A., Sansone L.A., Int. J. Psychiatry Med., 2003, 33 (1), 103.


67. Serebruany V.L. et al., Am. J. Cardiol., 2001, 87, 1398.


68. Serebruany V.L. et al., Am. J. Med., 2006, 119, 113.


69. Shaw D.M. et al., Br. J. Psychiatry, 1986, 149, 515.


70. Sindrup S.H. et al., Clin. Pharmacol. Ther., 1992, 52, 547.


71. Spigset O. et al., J. Clin. Psychiatry, 1996, 57, 39.


72. Spigset O. et al., Br. J. Clin. Pharmacol., 1997, 44, 295.


73. Taddio A. et al., J. Clin. Pharmacol., 1996, 36, 42.


74. Timmerman L. et al., Int. Clin. Psychopharmacol., 1987, 2, 239.


75. Trenque T. et al., Pharmacoepidemiol. Drug Safety, 2002, 11, 281.


76. von Knorring A.L. et al., J. Clin. Psychopharmacol/, 2006, 26 (3), 311.


77. van Melle J.P. et al., Psychosom. Med., 2004, 66, 814.


78. van Walraven C. et al., BMJ, 2001, 323, 655.


79. Wade A.G. et al., Br. J. Psychiatry, 1997, 170, 549.


80. Wagner K.D. et al., JAMA, 2003, 290, 1033.


81. Weintraub D. et al., Am. J. Geriatr. Psychiatry, 2015, 23 (11), 1127.


82. Wright S.et al., Br. J. Clin. Pharmacol., 1991, 31, 209.


83. Zeskind P.S., Stephens L.E., Pediatrics, 2004, 113, 368.


84. Zeskind P.S. et al., Pediatr. Res., 2005, 57, 1624.